PB 11 of 2024
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2024
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 30/01/2024
Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
Contents
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments—Additional designated brands effective from 1 June 2024
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
(1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2024.
(2) This instrument may also be cited as PB 11 of 2024.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | The day after this instrument is registered. |
|
2. Schedule 1 | 1 June 2024. | 1 June 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments—Additional designated brands effective from 1 June 2024
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Section 5 (after table item dealing with the brand Cal-500 of the drug Calcium in the form Tablet, chewable, 500 mg (as carbonate)
Insert:
Largactil | Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | Injection |
Largactil | Chlorpromazine | Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL | Oral |
Largactil | Chlorpromazine | Tablet containing chlorpromazine hydrochloride 100 mg | Oral |
Largactil | Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral |
2 Section 5 (after table item dealing with the brand Oxytrol of the drug Oxybutynin in the form Transdermal patches 36 mg, 8
Insert:
Neulactil | Periciazine | Tablet 10 mg | Oral |
Neulactil | Periciazine | Tablet 2.5 mg | Oral |